The Rosenman Innovators

Helping entrepreneurs bring life-changing healthtech to market in a big way. Applications for the 2021 cycle are now closed. Demo Day is June 10.

Jumpstart Your Innovation

Apply to be a Rosenman Innovator.

Connect with people who can speed up your scale-up in healthtech: subject matter experts, clinicians, partners and investors. Applications for 2021 are now closed. Investors: contact us to learn how to get involved.
Contact Us

Our hands-on mentorship, guidance, and the program’s suite of benefits help you navigate the path to commercialization like the insider you will soon be.

Have a question? See our FAQ below.

How It Works

All sessions are virtual.

Each spring, we invite startups in diagnostics, digital health, health services, and medical devices to pitch our panel of judges (a mix of financial/strategic investors, subject matter expertise and clinicians).

The judges select 10-12 companies who:

Receive customized and strategic coaching in communications, product development, IP, clinical/regulatory, reimbursement, marketing, and business strategy from our network of experts.

Receive insight and recommendations from our team on how to hone their investor pitch deck, and get exposure to a select group of motivated investors and industry partners. Previous Innovators have had investments made in their Series A rounds as a result of this program.

Win valuable in-kind prizes to help accelerate progress.

Join their fellow Rosenman Innovator companies to pitch a group of motivated investors and industry partners in an online demo day, followed by one-on-one meetings.

Who Can Apply

The Rosenman Innovators program is open to early-stage healthtech companies (up to and including Series A investment) based anywhere in the world.

No university affiliation is required.

If you have submitted an application in previous years but didn’t make it to the final cohort, we welcome you to apply again if your company has made progress.

Special Track: TB Diagnostics

Are you developing a technology to diagnose and treat tuberculosis? Have you thought about adapting your SARS-CoV-2 diagnostic technology to the biggest killer globally every year in infectious disease?
This year, we offer an opportunity for relevant companies/academic developers. If selected for the 2021 Rosenman Innovator cohort, you will be connected to partners at the Rapid Research in Diagnostics Development (R2D2) for TB Network who can provide specimens to further develop your diagnostic technology, facilitate clinical trials and connect you to key stakeholders.

Timeline

Innovators timeline

Investment Partners

A core group of investors supports the Rosenman Innovator program and the Institute through the year.

Testimonials

“Tiatros is very lucky to be a Rosenman Innovator. The program fostered our collaboration with the San Francisco Veteran Affairs Health Care System. We look forward to continuing to explore ways to serve Veterans in the VA system.”

Kimberlie Cerrone
CEO & Founder, Tiatros

“The Rosenman Innovators program helped Moray Medical with wonderful mentors and services (including access to the very impressive Gore Innovation Center) during the program. What has been even better is the continuing support of the Rosenman Institute community after the program, including an introduction to the lead investor of our recent $3.3 million round!”

Mark Barrish
CEO & Co-Founder, Moray Medical

“The Rosenman Innovator program was a fantastic experience and opportunity to get exposure to seed-stage healthcare investors and other industry stakeholders. We met two investors who participated in our round through the program.”

Ade Adesanya
Co-Founder & President, Moving Analytics

“We connected with early-stage investors key to closing our seed round and raising more than $2 million in grant funding. The services provided by Cannon Quality Group included more than six months of manufacturing in a controlled environment and strategic continued input to our QMS that helped us advance significantly over a short period of time.”

Maryam Parviz
CEO, SDIP Innovations

“Through Rosenman Innovators, we were able to partner with Bayflex Solutions to conduct essential mechanical and stress testing of our product.”

Ben Holmes
CEO, Nanochon

“The Innovator program connected us with mentors who were successful founders, sophisticated investors, and scientific experts. This unique model enabled us to accelerate our progress over a few short months, successfully raise our seed round, and expand our advisory board. We have loved being a part of the Rosenman community and highly recommend the Rosenman Innovator program to any medical device or technology startup! “

Rui Jing Jiang
CEO & Co-Founder, Avisi Technologies

“The Rosenman Innovator program was game-changing for our company. We [met] several highly-experienced mentors whose guidance helped us make drastic changes in our organization and strategy… and optimize our commercial path.”

Ted Abraham, MD
Founder, Perceptive Navigation

“Liv Labs adopted a more aggressive plan and visionary scope as a result of intensive peer and investor mentoring in preparation for the Rosenman Innovator program pitch.”

Melody Roberts
CEO, Liv Labs

In-Kind Services

Our participating service partners will choose the recipients of their services from among the Rosenman Innovator cohort. Criteria include technology, market potential, and how much a startup would benefit from a particular service.

AWS Activate
AWS Activate

Cloud infrastructure and services

Bayflex
Bayflex

Materials testing

Basil Systems
Basil Systems

Regulatory, quality, and due diligence research

Brown Rudnick
Brown Rudnick

IP strategy legal session

Cannon Quality Group
Cannon Quality Group

Lab bench space, environmental room, quality management services

Charles River
Charles River

Preclinical support

Experien Group
Experien Group

Regulatory services

Galen Data
Galen Data

Cloud data storage, visualization, & analysis

iO life science
iO life science

Design & engineering consultation, prototyping

Kilpatrick Townsend
Kilpatrick Townsend

IP strategy & counsel

LOK North America
LOK North America

Canadian regulatory & QMS

Maynard Cooper
Maynard Cooper

IP strategy and consultation corporate advisory services

Mingletoe
Mingletoe

Messaging strategy

PaxMed International
PaxMed International

Support with regulatory affairs

Perkins Coie
Perkins Coie

IP strategy session

Redox
Redox

Platform to exchange EHR data

San Francisco VA Health Care System
San Francisco VA Health Care System

Strategic clinical consultation

Strategic Marketing Innovations
Strategic Marketing Innovations

Strategy for securing federal funding

UCSF Clinical Innovation Center
UCSF Clinical Innovation Center

Consultation on startup strategy and UCSF partnership

Young Basile
Young Basile

IP and startup legal support

Frequently Asked Questions

If you can’t find your answers, please contact us here.

Our company is not based in California or the United States. Are we eligible?
We are not affiliated with a university. Does that affect our application in any way?
Our company is developing a digital technology. Do you only take medical devices?
We are not incorporated yet. Should we apply?
We do not yet have any funding. Are we eligible?
Are there any specific requirements re: disease or condition that our technology targets?